Revance announces the U.S. launch of the Teoxane RHA Collection with mepivacaine, replacing lidocaine as the anesthetic in its dermal filler products.
Revance has introduced the Teoxane RHA Collection with mepivacaine in the United States, replacing lidocaine as the anesthetic component in its hyaluronic acid fillers. The change marks the first major anesthetic update in dermal fillers in nearly 20 years, according to the company.
FDA Approval and Patent Details
The Teoxane RHA Collection with mepivacaine received FDA approval in 2023. The formulation is patented exclusively by Teoxane for use in dermal fillers. The describes the update as a deliberate, research-based innovation focused on patient care.
Mepivacaine Profile and Usage History
Although new to the aesthetic market, mepivacaine has been used therapeutically for more than 60 years. It shares the same mechanism of action as lidocaine but causes less local vasodilation. This reduced vasodilation may lower the chance of injection site reactions such as bruising, says the company.
Clinical Study Outcomes
Preclinical and clinical studies compared RHA Redensity with mepivacaine to RHA Redensity with lidocaine, as well as RHA 4 with both anesthetics. The studies found similar rheology, effective pain control, and no change in aesthetic outcomes. The safety profile remained consistent.
Leadership Commentary
“The development of the Teoxane RHA Collection with Mepivacaine exemplifies Teoxane’s commitment to innovation,” says Valérie Taupin, founder and CEO of Teoxane. “Mepivacaine represents the first major advancement in pain management in fillers in nearly two decades. It provides an anesthetic effect comparable to currently available products, but with reduced local vasodilation, as demonstrated in the recent article published in RSC Pharmaceutics, 2025, which may result in less bruising. We are proud to bring this patented innovation to providers and offer great patient comfort. Teoxane is leading the way in a next-generation approach to optimal patient experience in aesthetics.”
“It’s incredibly rewarding to help bring the next evolution of RHA to the U.S. market. The addition of mepivacaine reflects our commitment to advancing the patient experience without compromising the outcomes providers have come to expect from the RHA Collection by Teoxane. We’re proud to lead the way in innovation that matters to both patients and practices,” adds Jeff Bedard, founder and CEO, Revance.
Photo: Revance
